398 related articles for article (PubMed ID: 27571185)
1. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B
J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
J Clin Endocrinol Metab; 2017 Aug; 102(8):2770-2780. PubMed ID: 28609832
[TBL] [Abstract][Full Text] [Related]
3. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-Induced Thyroiditis and Colitis-Presentation and Resolution on Serial FDG PET/CT.
Nawwar AA; Searle J; Lyburn ID
Clin Nucl Med; 2021 Feb; 46(2):e121-e122. PubMed ID: 32969909
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
6. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-Induced Thyroiditis.
Imblum BA; Baloch ZW; Fraker D; LiVolsi VA
Endocr Pathol; 2019 Jun; 30(2):163-167. PubMed ID: 31111437
[TBL] [Abstract][Full Text] [Related]
8. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
[TBL] [Abstract][Full Text] [Related]
9. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
[TBL] [Abstract][Full Text] [Related]
10. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.
Sakurai K; Fukazawa H; Arihara Z; Yoshida K
Tohoku J Exp Med; 2010 Sep; 222(1):39-44. PubMed ID: 20814176
[TBL] [Abstract][Full Text] [Related]
12. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.
Orlov S; Salari F; Kashat L; Walfish PG
J Clin Endocrinol Metab; 2015 May; 100(5):1738-41. PubMed ID: 25751110
[TBL] [Abstract][Full Text] [Related]
13. [Development of destructive thyroiditis and diabetes mellitus after three injections of pembrolizumab for skin melanoma].
Glibka AA; Mel Nichenko GA; Mikhina MS; Mazurina NV; Kharkevich GY
Probl Endokrinol (Mosk); 2021 Feb; 67(2):20-27. PubMed ID: 34004100
[TBL] [Abstract][Full Text] [Related]
14. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
16.
Eshghi N; Garland LL; Nia E; Betancourt R; Krupinski E; Kuo PH
J Nucl Med Technol; 2018 Sep; 46(3):260-264. PubMed ID: 29599403
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab Exacerbates Thyroid Diseases Shown on FDG PET/CT.
Wang X; Wang J; Yang X; Zhao H; Huo L
Clin Nucl Med; 2020 Dec; 45(12):1010-1012. PubMed ID: 32910056
[TBL] [Abstract][Full Text] [Related]
18. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
[TBL] [Abstract][Full Text] [Related]
19. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
Garon-Czmil J; Petitpain N; Rouby F; Sassier M; Babai S; Yelehe-Okouma M; Weryha G; Klein M; Gillet P
Fundam Clin Pharmacol; 2019 Apr; 33(2):241-249. PubMed ID: 30308083
[TBL] [Abstract][Full Text] [Related]
20. Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies.
Frelau A; Palard-Novello X; Jali E; Boussemart L; Dupuy A; James P; Devillers A; Le Jeune F; Edeline J; Lesimple T; Girard A
Cancer Immunol Immunother; 2021 Mar; 70(3):679-687. PubMed ID: 32880684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
